Comparison of docetaxel/cisplatin dosages of 75/60 and 60/60 mg/m2 for the treatment of non-small cell lung cancer

Kim,Kyu-Sik; Oh,In-Jae; Ban,Hee-Jung; Cho,Hyun-Ju; Kwon,Yong-Soo; Kim,Yu-Il; Lim,Sung-Chul; Na,Kook-Joo; Song,Sang-Yun; Choi,Song; Choi,Yoo-Duk; Kim,Young-Chul

doi:10.3892/etm.2012.597

August 2012 Volume 4 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August 2012 Volume 4 Issue 2

Full Size Image

Article

Comparison of docetaxel/cisplatin dosages of 75/60 and 60/60 mg/m2 for the treatment of non-small cell lung cancer

Authors:
- Kyu-Sik Kim
- In-Jae Oh
- Hee-Jung Ban
- Hyun-Ju Cho
- Yong-Soo Kwon
- Yu-Il Kim
- Sung-Chul Lim
- Kook-Joo Na
- Sang-Yun Song
- Song Choi
- Yoo-Duk Choi
- Young-Chul Kim
View Affiliations / Copyright

Affiliations: Lung and Esophageal Cancer Clinic, Chonnam National University, Hwasun Hospital, Hwasun, Jeonnam, Republic of Korea, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea
Pages: 317-322
|
Published online on: June 1, 2012

https://doi.org/10.3892/etm.2012.597
Expand metrics +

Abstract

A combination of docetaxel (D) and cisplatin (P) is one of the standard regimens for the initial treatment of advanced non-small cell lung cancer (NSCLC). Yet, the toxicity of D administered at 75 mg/m2 in three weekly doses to patients is a concern. The aim of this study was to assess the efficacy of a lower combination dose, 60 mg/m2 of D and 60 mg/m2 of cisplatin (P), as a treatment for NSCLC. In this randomized, phase III trial, we compared the response rates (RRs) and toxicity profiles of two combination regimens, D/P 75/60 vs. 60/60 mg/m2, to patients with stage IIIB or IV NSCLC. A total of 132 patients were randomized to the 75/60 (n=65) or 60/60 (n=67) dosage group. Non-inferiority of 60/60 group compared to the 75/60 group was confirmed by the RR (38.5% for the 75/60 group and 40.3% for the 60/60 group, 95% confidence interval -14.8 to 18.5, meeting the predefined non-inferiority criterion). The dose reduction rate and incidence of grade 3-4 neutropenia were significantly higher in the 75/60 group. The incidence of neutropenia was significantly higher in those with the non-expressing genotype (GG) compared to the AG or AA genotypes of CYP3A5. We determined that DP 60/60 was not inferior to DP 75/60 in RR, and that the reduced combination dosage provides a better safety profile for patients.

View Figures

View References

1.	Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 346:92–98. 2002. View Article : Google Scholar
2.	Fossella F, Pereira JR, von Pawel J, et al: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol. 21:3016–3024. 2003. View Article : Google Scholar : PubMed/NCBI
3.	Okamoto H, Watanabe K, Segawa Y, et al: Phase II study of docetaxel and cisplatin in patients with previously untreated metastatic non-small cell lung cancer. Int J Clin Oncol. 5:316–322. 2000. View Article : Google Scholar
4.	Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ and Gelboin HV: Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics. 8:391–401. 1998. View Article : Google Scholar
5.	Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF and Rebbeck TR: Increased transcriptional activity of the CYP3A4^*1B promoter variant. Environ Mol Mutagen. 42:299–305. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Kuehl P, Zhang J, Lin Y, et al: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 27:383–391. 2001. View Article : Google Scholar : PubMed/NCBI
7.	van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G and Sparreboom A: Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res. 6:2598–2603. 2000.PubMed/NCBI
8.	Bruno R, Hille D, Riva A, et al: Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 16:187–196. 1998.PubMed/NCBI
9.	Hoffmeyer S, Burk O, von Richter O, et al: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 97:3473–3478. 2000. View Article : Google Scholar : PubMed/NCBI
10.	Pan JH, Han JX, Wu JM, Huang HN, Yu QZ and Sheng LJ: MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small cell lung cancer. Respiration. 78:49–55. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Newcombe RG: Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 17:873–890. 1998. View Article : Google Scholar : PubMed/NCBI
12.	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar
13.	Gandara DR, Mack PC, Li T, Lara PN Jr and Herbst RS: Evolving treatment algorithms for advanced non-small cell lung cancer: 2009 looking toward 2012. Clin Lung Cancer. 10:392–394. 2009. View Article : Google Scholar
14.	Turolo S, Tirelli AS, Ferraresso M, et al: Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep. 62:1159–1169. 2010. View Article : Google Scholar : PubMed/NCBI